PSMA-Positive mHSPC: Integrating Lu-177 Vipivotide Tetraxetan With ADT + ARPI

Authored by Arun Azad, published on 2026-08-20 00:21:36.0

PSMAddition Evidence-Fit Note

Use the pivotal PSMAddition population to judge evidence fit without treating trial eligibility criteria as universal FDA-label requirements. PSMAddition evaluated a treatment-naive or minimally treated PSMA-positive metastatic hormone-sensitive prostate cancer population receiving ADT + ARPI with or without Lu-177 vipivotide tetraxetan. Key evidence-fit features included: - ECOG performance status 0–2. - PSMA-positive disease confirmed with 68Ga-PSMA-11 PET/CT and central review. - Up to 45 days of prior ADT before study entry. - Up to 45 days of prior androgen receptor-directed therapy before study entry. - Standard-of-care treatment consisted of ADT + ARPI. The study did not provide a randomized comparison against a docetaxel-containing triplet. Use these features to judge how closely an individual patient resembles the pivotal population; do not automatically convert trial-specific criteria into label exclusions.
Consider a clinical trial

Consider clinical trial participation at key treatment-selection and sequencing decision points when an appropriate study is available. Clinical trials may be particularly relevant when treatment sequencing, combinations with other intensification strategies, PSMA-targeted approaches, or other emerging therapies remain uncertain. Trial participation should complement evidence-based standard care and should not create avoidable delay in clinically necessary treatment.
Confirm metastatic hormone-sensitive prostate cancer

Confirm established metastatic hormone-sensitive prostate cancer and assess readiness for systemic treatment intensification. Confirm that the patient is entering a metastatic hormone-sensitive prostate cancer treatment pathway. Assess the clinical factors needed before treatment selection: - Confirm metastatic disease and hormone-sensitive disease state. - Review disease distribution, volume, symptoms, and clinical tempo. - Assess performance status and major comorbidities. - Review marrow and renal reserve relevant to systemic and radioligand therapy. - Confirm suitability for ongoing androgen deprivation therapy and an ARPI. - Review prior systemic treatment and duration of prior ADT or ARPI exposure. - Confirm access to appropriate multidisciplinary and nuclear-medicine expertise when radioligand therapy is being considered. PSMA imaging eligibility is addressed in the subsequent decision node.
- PSMA-positive on an approved PSMA PET and clinically appropriate for Lu-177 + ARPI?
  
  Determine whether the patient meets current PSMA-imaging requirements and is clinically suitable for Lu-177 vipivotide tetraxetan in combination with ARPI therapy. Current FDA eligibility requires PSMA-positive metastatic androgen pathway modulation-naive or -sensitive prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer. Select patients using Locametz or another FDA-approved PSMA PET product based on tumor PSMA expression. Also assess clinical feasibility, including: - Ability to continue ADT and an ARPI. - Marrow reserve. - Renal function. - Performance status and competing comorbidities. - Ability to comply with radiopharmaceutical treatment logistics and radiation-safety requirements. Do not impose trial-specific treatment-duration or performance-status criteria as universal label exclusions. Answer YES when PSMA imaging and clinical suitability support consideration of Lu-177 + ARPI. Answer NO when PSMA criteria are not met or radioligand therapy is not clinically appropriate or feasible.
  - No — Not eligible / appropriate for Lu-177 + ARPI
    - Open: Standard mHSPC Intensification Pathway
      
      Use established mHSPC intensification strategies when Lu-177 + ARPI is not appropriate or PSMA eligibility requirements are not met. Transition to the standard mHSPC treatment pathway. Treatment selection should integrate: - Disease volume and distribution. - De novo versus metachronous metastatic presentation. - Symptoms and clinical tempo. - Fitness for ARPI and/or docetaxel-based intensification. - Comorbidities and toxicity priorities. - Patient preferences and treatment access. - Potential role of prostate-directed radiotherapy when clinically appropriate. Do not use lack of eligibility for Lu-177 as a reason to undertreat otherwise appropriate metastatic hormone-sensitive disease.
  - Yes — Eligible for Lu-177 + ARPI
    - Select treatment strategy
      
      For an eligible PSMA-positive patient, select the intensification strategy based on evidence fit, disease characteristics, treatment feasibility, toxicity, logistics, and patient preference. Discuss Lu-177 + ADT + ARPI alongside other established mHSPC intensification strategies rather than assuming that radioligand therapy is universally preferred. Consider: - Disease volume, distribution, symptoms, and tempo. - De novo versus metachronous metastatic presentation. - PSMA expression and disease heterogeneity. - Prior ADT or ARPI exposure. - Fitness for docetaxel-containing intensification. - Marrow and renal reserve. - Expected hematologic and renal toxicity. - Treatment schedule and radiopharmaceutical logistics. - Radiation-safety requirements. - Access, travel burden, and patient preferences. PSMAddition demonstrated a significant radiographic progression-free survival benefit for Lu-177 + ARPI compared with ARPI alone. Overall-survival data were immature at the time of FDA approval. There is no randomized comparison establishing superiority of Lu-177 + ADT + ARPI over a contemporary docetaxel-containing triplet.
      - Lu-177 vipivotide tetraxetan + ADT + ARPI
        
        Administer Lu-177 vipivotide tetraxetan with ongoing ADT + ARPI in an appropriate PSMA-positive patient with metastatic hormone-sensitive prostate cancer. Use lutetium Lu 177 vipivotide tetraxetan in combination with continued ADT + ARPI for an appropriate PSMA-positive patient. Treatment: - Lu-177 vipivotide tetraxetan 7.4 GBq (200 mCi) IV every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity. - Continue medical or surgical castration. - Continue the selected ARPI according to its prescribing information. PSMAddition demonstrated a significant improvement in radiographic progression-free survival with Lu-177 + ARPI compared with ARPI alone. Overall-survival data were immature at the time of FDA approval. Dose & toxicity management: - Treatment may be withheld, dose-reduced, or permanently discontinued for toxicity. - A single 20% dose reduction to 5.9 GBq (160 mCi) is permitted; do not re-escalate. - If toxicity subsequently requires another dose reduction, discontinue Lu-177. - Monitor particularly for myelosuppression, renal toxicity, xerostomia, gastrointestinal toxicity, fatigue, and radiation-related safety considerations.
        
        Monitoring during Lu-177 therapy
        
        Before and during treatment, assess marrow and renal function, treatment-related toxicity, disease status, and ability to safely continue Lu-177. Monitor before and during each treatment course: - Complete blood count, including hemoglobin, platelets, leukocytes, and neutrophils. - Serum creatinine and calculated creatinine clearance. - Clinical symptoms and performance status. - Xerostomia, nausea, gastrointestinal toxicity, and fatigue. - Evidence of disease progression. - Toxicity from the accompanying ARPI according to the selected agent. Supportive measures: - Encourage adequate hydration. - Encourage frequent urination around treatment to reduce urinary radiation exposure. - Provide radiation-safety instructions according to institutional and regulatory requirements. Reassess toxicity and recovery before each subsequent Lu-177 dose.
        
        Is continued Lu-177 treatment clinically appropriate?
        
        Before each subsequent dose, determine whether treatment should continue, be withheld or dose-reduced, or be permanently discontinued. Answer YES when: - There is no disease progression requiring a change in treatment strategy. - Treatment-related toxicity remains acceptable or has recovered sufficiently. - Marrow and renal function permit continued therapy. - No new clinical factor makes radioligand treatment inappropriate. Treatment may be temporarily withheld to allow recovery from toxicity. A single 20% dose reduction to 5.9 GBq (160 mCi) may be used when indicated; do not re-escalate. Answer NO when: - Disease progression requires transition to another disease-state pathway. - Toxicity is unacceptable despite appropriate interruption or dose modification. - A further dose reduction would be required after the permitted single dose reduction. - Severe or recurrent marrow or renal toxicity warrants permanent discontinuation. - Treatment cannot safely continue for another clinical reason. Avoid continuing Lu-177 solely to complete six doses when progression or unacceptable toxicity has occurred.
        
        Yes — Continue Lu-177
        
        Continue planned course
        
        Continue Lu-177 vipivotide tetraxetan with ongoing ADT + ARPI, up to the planned 6-dose course, as long as there is no disease progression or unacceptable toxicity. If continued treatment remains clinically appropriate, proceed with the next planned dose of Lu-177 vipivotide tetraxetan. Treatment plan: - Continue Lu-177 vipivotide tetraxetan every 6 weeks. - Continue ADT / castration maintenance. - Continue the selected ARPI according to its prescribing information. - Continue treatment for up to 6 total doses, or until disease progression or unacceptable toxicity. If treatment was previously withheld for toxicity, resume only after adequate recovery. If a dose reduction was required: - A single 20% dose reduction to 5.9 GBq (160 mCi) is permitted. - Do not re-escalate after dose reduction. - If further dose reduction would be required, discontinue Lu-177 rather than continue at a lower dose. Continue close monitoring of hematologic tolerance, renal function, symptoms, and overall treatment feasibility.
        
        Longitudinal mHSPC Follow-Up
        
        Continue longitudinal follow-up during ADT-based systemic therapy, including monitoring of treatment response, toxicity, symptoms, and readiness for future treatment transitions. After completion or discontinuation of Lu-177 intensification, continue structured follow-up for metastatic hormone-sensitive prostate cancer. Follow-up should include: - Disease-specific history and interval symptoms. - PSA monitoring. - Confirmation that castration is maintained during ADT. - CBC, creatinine, and other laboratory monitoring as clinically indicated. - Ongoing assessment of ARPI-related toxicity. - Monitoring for late or persistent toxicity after Lu-177. - Evaluation of bone health, functional status, and quality of life. - Reassessment for progression to a new disease state and need for treatment sequencing. Imaging should be obtained when clinically indicated and when results will inform management decisions. Follow-up frequency should be individualized, but regular clinical follow-up remains essential during ADT-based therapy.
        
        No — Stop / transition
        
        Stop Lu-177 and transition to the appropriate disease-state pathway
        
        Discontinue Lu-177 when progression, toxicity, or another clinical factor makes continued radioligand therapy inappropriate, and transition to the next appropriate prostate cancer management pathway. Do not continue Lu-177 solely to complete the planned course if ongoing treatment is no longer clinically appropriate. Transition to the next management pathway when any of the following occurs: - Radiographic or clinical progression requiring a change in treatment strategy. - Unacceptable toxicity despite interruption or permitted dose reduction. - Persistent or severe myelosuppression. - Renal toxicity or other treatment-limiting adverse effects. - Inability to safely continue radioligand therapy for logistical or clinical reasons. Next-step pathway selection should be individualized according to: - Current disease state. - Prior treatment exposure. - Performance status and organ function. - Symptom burden and tempo of progression. - Patient goals and treatment preferences. This node is a handoff node; the specific downstream pathway should be selected outside this algorithm.
      - Open: ARPI-Based mHSPC Intensification Pathway
        
        Transition to an established ADT + ARPI strategy when this is selected instead of upfront Lu-177 radioligand therapy. Use the dedicated mHSPC pathway to select an appropriate ARPI-based intensification strategy. Selection should consider: - Disease volume, distribution, and clinical tempo. - De novo versus metachronous metastatic disease. - Symptoms and performance status. - Comorbidities and ARPI-specific toxicity profile. - Genomic findings when treatment-relevant. - Patient preferences, access, and treatment burden. ADT + ARPI remains an established treatment backbone for metastatic hormone-sensitive prostate cancer. Do not interpret this branch as evidence that ARPI-based therapy is inferior for every PSMA-positive patient; treatment selection should remain individualized.
      - Open: Docetaxel-Containing mHSPC Intensification Pathway
        
        Consider a docetaxel-containing intensification strategy when chemotherapy-based triplet therapy is clinically appropriate. Use the dedicated mHSPC pathway when a docetaxel-containing intensification strategy is being considered. Assess: - Fitness for docetaxel. - De novo versus metachronous presentation. - Disease volume and risk. - Symptoms and clinical tempo. - Comorbidities and expected chemotherapy toxicity. - Patient goals and treatment preferences. Current standard triplet strategies combine docetaxel with ADT + an appropriate ARPI. PSMAddition compared Lu-177 + ADT + ARPI with ADT + ARPI and did not establish a randomized comparison against a docetaxel-containing triplet. Do not assume superiority of one strategy over the other in the absence of direct comparative evidence.

tos privacy PSMAddition (NCT04720157). Phase III study of 177Lu-PSMA-617 plus standard of care versus standard of care in metastatic hormone-sensitive prostate cancer.European Association of Urology. EAU Guidelines on Prostate Cancer: Treatment of Metastatic Prostate Cancer. 2026.FDA. Lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naive or -sensitive prostate cancer. July 31, 2026.PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) Prescribing Information. Dosage Modifications for Adverse Reactions.European Association of Urology. EAU Guidelines on Prostate Cancer: Follow Up. 2026.